Genome-wide association studies have revealed that common noncoding variants in MTNR1B (encoding melatonin receptor 1B, also known as MT 2 ) increase type 2 diabetes (T2D) risk 1,2 . Although the strongest association signal was highly significant (P < 1 × 10 −20 ), its contribution to T2D risk was modest (odds ratio (OR) of ~1.10-1.15) 1-3 . We performed large-scale exon resequencing in 7,632 Europeans, including 2,186 individuals with T2D, and identified 40 nonsynonymous variants, including 36 very rare variants (minor allele frequency (MAF) <0.1%), associated with T2D (OR = 3.31, 95% confidence interval (CI) = 1.78-6.18; P = 1.64 × 10 −4 ). A four-tiered functional investigation of all 40 mutants revealed that 14 were nonfunctional and rare (MAF < 1%), and 4 were very rare with complete loss of melatonin binding and signaling capabilities. Among the very rare variants, the partial- or total-loss-offunction variants but not the neutral ones contributed to T2D (OR = 5.67, CI = 2.17-14.82; P = 4.09 × 10 −4 ). Genotyping the four complete loss-of-function variants in 11,854 additional individuals revealed their association with T2D risk (8,153 individuals with T2D and 10,100 controls; OR = 3.88, CI = 1.49-10.07; P = 5.37 × 10 −3 ). This study establishes a firm functional link between MTNR1B and T2D risk.
Disruption of central and peripheral circadian rhythms, including the pancreatic clock, may lead to metabolic disorders and type 2 diabetes (T2D) 4, 5 . The neurohormone melatonin (MLT) is mainly secreted from the pineal gland in a circadian pattern, with higher levels being observed during the night. MLT targets two high-affinity G proteincoupled receptors (GPCRs), melatonin receptor 1A (also known as MT 1 , encoded by MTNR1A) and MT 2 (encoded by MTNR1B), which modulate both G i protein-adenylyl cyclase and ERK1 and ERK2 (ERK1/2) pathways 6, 7 . Genome-wide association studies (GWAS) recently revealed an association between SNPs in MTNR1B and T2D risk in humans 1, 2 . However, the contribution of these SNPs to T2D risk was typical for common alleles [1] [2] [3] . So far, the effects seen for all common T2D-associated SNPs identified by GWAS explain less than 10% of T2D heritability 3, 8 . The missing heritability of T2D might be partially explained by numerous rare mutations that have a stronger functional effect 9 . However, rare variant effects cannot easily be identified via GWAS because of problems of statistical power. Such rare variant effects have been discovered in GWAS-identified susceptibility genes for type 1 diabetes 10, 11 and hypertriglyceridemia 12 by large-scale resequencing. Recently, two T2D-associated genes identified by GWAS (HHEX and KCNJ11) were sequenced in 13,715 individuals, and an excess of rare recent variants were found, consistent with explosive population growth 13 . The authors of this study suggested that increased disease (T2D) risk in contemporary Rare MTNR1B variants impairing melatonin receptor 1B function contribute to type 2 diabetes A full list of author affiliations appears at the end of the paper. l e t t e r s populations might be heavily influenced by the distribution of rare variants. However, they did not test for T2D association or function for any of the variants 13 . Based on the strong evidence for the association between the MTNR1B gene and T2D risk, together with the fact that MT 2 belongs to the superfamily of GPCRs that are privileged drug targets, we wanted to identify rare nonsynonymous variants with putative effect on the function of MT 2 that associate with T2D risk. We sequenced the two exons of MTNR1B in 7,632 unrelated European individuals with known glycemic status, including 2,186 subjects with T2D (Supplementary Table 1 ). We identified 40 nonsynonymous variants, including two common SNPs (MAF >1%; rs8192552 encoding a G24E variant and rs61747139 encoding a K243R variant), two less common variants (MAF between 0.1 and 1%; rs61746674 encoding an R138C variant and rs8192553 encoding an R231H variant) and 36 very rare variants (MAF <0.1%), which were not previously listed in public SNP databases ( Fig. 1 and Table 1) . No association was found between T2D risk and either of the common SNPs (rs8192552 or rs61747139) ( Table 1) . The rarer variants were analyzed by pooling them according to their MAFs: we analyzed one pool of the two variants with MAFs between 0.1 and 1% and a second pool of the 36 variants with MAFs of <0.1%. By using the kernel-based adaptive cluster (KBAC) method 14 embedded in a logistic regression model, we found that the variants with intermediate MAFs did not associate with T2D risk (N controls = 4,804; N cases = 2,186, where cases are individuals with T2D; odds ratio (OR) = 1.00, 95% confidence interval (CI) = 0.40-3.20; P = 0.81; Table 1 ), whereas the rarest variants (with MAF <0.1%) contributed strongly to increased T2D risk (OR = 3.31, 95% CI = 1.78-6.18; P = 1.64 × 10 −4 ; Table 1 ). Fig. 1b ) and a tenfold variation in the number of [ 125 I]MLT binding sites (Fig. 2a) . Notably, four MT 2 mutants (the A42P, L60R, P95L and Y308S variants) showed no [ 125 I]MLT binding ability ( Fig. 2a and Supplementary Fig. 1b ). These same mutants did not activate downstream G i protein-dependent (Fig. 2b,c ) or ERK1/2 ( Fig. 2d) signaling pathways. Ten additional mutants with intact MLT binding (the W22L, A52T, A74T, R138C, R138H, R138L, L166I, R222H, R330W and I353T variants) showed impaired G i protein-dependent signaling, whereas the other mutants had similar activity to the wild-type MT 2 receptor (Fig. 2b,c) .
Of the ten mutants with impaired G i protein signaling, only the R138C variant was unable to activate the ERK1/2 pathway, indicating the pathway-specific effect of the other nine mutants (Fig. 2d) . It is noteworthy that all of the variants that ablated MLT binding and all but one of the variants that inhibited signaling downstream of MT 2 were very rare and had MAFs <0.1%.
The four MT 2 mutants deficient in MLT binding contain amino acid substitutions in the predicted transmembrane domains I (p.Ala42Pro and p.Leu60Arg), II (p.Pro95Leu) and VII (p.Tyr308Ser) (Fig. 1) . The ten MT 2 mutants with impaired G i protein signaling have amino acid changes localized to the predicted I (p.Ala52Thr), II (p.Ala74Thr), III (p.Arg138Cys, p.Arg138His and p.Arg138Leu), IV (p.Leu166Ile) and V (p.Arg222His) transmembrane domains, N terminus (p.Trp22Leu), and the C terminus (p.Arg330Trp and p.Ile353Thr) (Fig. 1) . Four of these alterations affect conserved motifs in MT 2 : p.Tyr308Ser alters a conserved NP(A)XXY motif (where X represents any amino acid), and p.Arg138Cys, p.Arg138Leu and p.Arg138His alter the D(N)RY motif, both of which are involved in GPCR activation 15 . A8S  A13V  G21S  W22L  G24E  A25T  P36S  A42P  A52T  L60R  A74T  P95L  G109A  M120I  M120V  S123R  V124I  R138C  R138H  R138L  Y141F  M146V  R154H  L166I  T201M  R222H  I223T  R231H  A234T  E237K  S238G  K243R  D246N  F250V  Y308S  R316H  R330W  A342V  I353T  A359Q  WT  A8S  A13V  G21S  W22L  G24E  A25T  P36S  A42P  A52T  L60R  A74T  P95L  G109A  M120I  M120V  S123R  V124I  R138C  R138H  R138L  Y141F  M146V  R154H  L166I  T201M  R222H  I223T  R231H  A234T  E237K  S238G  K243R  D246N  F250V  Y308S  R316H  R330W  A342V  I353T  A359Q WT
Figure 2 l e t t e r s
To further assess the observed deficits in MT 2 function, we compared our functional data with sequence-and structure-based predictions made by Polymorphism Phenotyping (PolyPhen-2) v2 software (Supplementary Table 2 ) 16 . By defining variants that were predicted to be 'possibly' or 'probably' damaging by PolyPhen-2 as loss-of-function mutants, we found 60% concordance between our functional data and the PolyPhen-2 predictions (Supplementary Table 3 ). Furthermore, the software predicted 30% false positive and 7.5% false negative loss-of-function variants compared to our own data. It is noteworthy that the most recent version of PolyPhen-2 (v2.0.23; released 9 December 2010) is more sensitive than the previous version (v2.0.22), but it identified more potentially damaging variants that were not biologically confirmed (Supplementary Table 3) .
We then assessed whether the four total loss-of-function MT 2 variants had a significant effect on increased T2D risk, determining whether we could confirm what was previously observed for all rare variants with MAF <0.1%. We genotyped the portion MTNR1B encoding the A42P, L60R, P95L and Y308S variants in 11,854 additional French subjects, including 5,967 individuals with T2D. By analyzing these variants as a pool using the KBAC method embedded in a logistic regression model, we found that the A42P, L60R, P95L and Y308S variants had a strong and significant effect on increased T2D risk (N controls = 10,100; N cases = 8,153; OR = 3.88, 95% CI = 1.49-10.07; P = 5.37 × 10 −3 ; Table 2 ), confirming the association between the total loss of function of MT 2 variants and T2D risk. A study has described impaired G protein-dependent MT 2 function caused by an MTNR1B mutation encoding a p.Leu60Arg alteration 17 . No association with T2D was found, probably as a result of statistical power issues 17 , emphasizing the need for extensive composite sequencing-genotypingbiological studies in very large populations.
The pool of ten partial loss-of-function MT 2 variants (which had impaired G i protein signaling without MLT binding deficiency) showed a trend toward association with T2D risk (N controls = 4,804; N cases = 2,186; OR = 2.66, 95% CI = 1.01-7.00; P = 0.047; Table 2 ).
This suggests that G i protein-dependent signaling might contribute to T2D risk. Of note, the original group of 36 nonsynonymous variants with MAF <0.1% that associated with T2D ( Table 1) can be split into two categories after our current biological assessment: a group of 13 loss-of-function variants that are strongly associated with T2D risk (N controls = 4,804; N cases = 2,186; OR = 5.67, 95% CI = 2.17-14.82; P = 4.09 × 10 −4 ; Fig. 3 and Table 2 ) and a second group of 23 seemingly neutral variants that did not associate with T2D risk (Fig. 3 and Table 2) . Therefore, the association between rare nonsynonymous MTNR1B variants and T2D risk is further supported by the association of mutants that showed evidence of melatonin signaling impairment.
Based on RNA expression data, it has been reported that the GWASidentified at-risk allele for T2D at rs10830963 (located in the unique MTNR1B intron) was associated with increased MTNR1B transcript levels in human islets 18 . As pharmacological doses of MLT inhibit insulin secretion from murine β-cell lines 18, 19 , it was suggested that inhibiting MLT receptors could be a therapeutic avenue for T2D treatment 18 . Our functional analyses at the protein level, showing an association between defective MT 2 receptor function and T2D risk, suggest that the previously observed increased MTNR1B expression is not causal but could instead be a result of the absence of negative feedback regulatory events under conditions of impaired MT 2 receptor signaling. Plausible mechanisms are loss of the acute inhibitory effect of melatonin on insulin secretion or loss of the effect of melatonin on circadian rhythm entrainment. Hence, MLT receptor agonists that are currently prescribed for sleep and circadian rhythm disorders as well as for depression 20 may be beneficial for T2D therapy.
Our data confirm that resequencing GWAS-identified susceptibility genes for a complex disease (like T2D), followed by the careful biological evaluation of newly identified rare but potentially damaging variants, can contribute to a more complete picture of the genetic architecture of disease risk.
METhODs
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/.
Note: Supplementary information is available on the Nature Genetics website.
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ONLINE METhODs
The study design is summarized in Supplementary Figure 2 .
Study participants. Clinical characteristics and phenotypic data collected from the study populations are reported (Supplementary Table 1 ). Fasting plasma glucose levels and T2D status were determined for all participants. All subjects in this study were unrelated and of European ancestry. Sequencing of the two MTNR1B exons and genotyping of the four total loss-of-function MTNR1B mutations (encoding p.Ala46Pro, p.Leu60Arg, p.Pro95Leu and p.Tyr308Ser alterations) were performed in several general European cohort studies and T2D case-control studies (Supplementary Table 1 ). The non-diabetic subjects were obtained from five European studies: (i) the Data from the Epidemiological Study on the Insulin Resistance Syndrome (D.E.S.I.R.) cohort, which is a longitudinal study in the French general population, fully described elsewhere 21 , (ii) the Ely study, which was established in 1990 as a prospective population-based cohort study of the etiology and pathogenesis of T2D (ref. 22) , (iii) the Hertfordshire Cohort Study, which consists of men and women born between 1931 and 1939 and still residing in the English county of Hertfordshire, of whom almost 3,000 have been extensively characterized 23 , (iv) obese probands from French pedigrees of obesity who were recruited at CNRS UMR 8199 through an ongoing national media campaign 24 and (v) the French SU.VI.MAX study, which is a randomized double-blind, placebo-controlled primary prevention trial designed to assess the usefulness of daily supplementation with antioxidant vitamins and minerals in reducing the frequency of major health problems in industrialized countries 25 . In total, 685 individuals with T2D were ascertained from the five previously described studies. The majority of subjects with T2D were recruited from (i) the Endocrinology-Diabetology Department of the Corbeil-Essonnes Hospital 26 , (ii) the French Diabhycar/Diab2-Néphrogène/Surdiagène study 27 and (iii) the CNRS UMR 8199 (ref. 26) .
For each individual, glycemic status was defined according to the 1997 American Diabetes Association criteria 28 : normal glucose was defined as fasting plasma glucose levels of <6.1 mmol/l without treatment with antidiabetic agents, impaired fasting glucose was defined as fasting plasma glucose levels of ≥6.1 mmol/l and <7.0 mmol/l without treatment with antidiabetic agents, and T2D was defined as fasting plasma glucose levels of ≥7.0 mmol/l or by treatment with antidiabetic agents.
All samples used were collected with appropriate informed consent consistent with their use in the present study. All cohort studies followed ethical principles defined in the Helsinki declaration (revised in 1996), and they were approved by local ethical committees from Lille (France), Paris (France), Poitiers (France) and Cambridge (UK).
Sequencing. Sanger sequencing of the MTNR1B exons was performed in 7,632 unrelated European subjects, including 2,186 subjects with T2D. MTNR1B is located on human chromosome 11q21-q22 and encodes a 362-amino-acid protein (NM_005959.3 and NP_005950.1). The two MTNR1B exons were analyzed in five fragments using previously described primer sequences and PCR conditions 1 . Fragments were bidirectionally sequenced using the automated 3730xl DNA Analyzer (Applied Biosystems). Electrophoregram reads were assembled and analyzed using Variant Reporter software (Applied Biosystems). Each newly identified nonsynonymous mutation was confirmed by a second bidirectional Sanger sequencing reaction. The location of each variant was determined relative to the translation initiation codon using Human Genome Variation Society (HGVS) nomenclature for the description of sequence variations. The position of mutations was indicated according to the human genome build NCBI36/hg18.
Genotyping. Genotyping of the four total loss-of-function MTNR1B mutations (encoding p.Ala46Pro, p.Leu60Arg, p.Pro95Leu and p.Tyr308Ser amino acid substitutions) was performed in 14,909 additional unrelated European individuals. The DNA samples were pooled and screened by HighResolution Melting (HRM); samples that potentially contained sequence polymorphisms were studied individually using Sanger sequencing. We used the LightCycler 480 HRM Master kit (Roche Diagnostics) according to the manufacturer's protocol. Briefly, for genotyping of each mutation, 10 ng of DNA per sample was used in 5 µl of Master Mix (2×) with 1 µl of Primer Mix (4 µM) and 1.2 µl of MgCl 2 (25 mM (Supplementary Fig. 3 ), but acting conservatively, we chose to pool three DNA samples in each reaction. Each 384-well plate contained two positive controls: one well with only a mutated DNA sample and one well with a mutated sample and two wild-type DNA samples (Supplementary Fig. 3) . When an HRM profile matched the profile of a positive control, we resequenced the three DNA samples following a standard protocol. A total of 3,055 samples were both directly sequenced for the two MTNR1B exons and subsequently genotyped for the four mutations. We found 100% concordance (3,055/3,055) between the two protocols.
Statistical analyses. We independently assessed the effect of frequent variants (with MAF ≥1%) on T2D risk using logistic regression adjusted for age, gender and body mass index (BMI) under an additive model. Rarer variants were analyzed by pooling them on the basis of their MAFs (between 0.1 and 1% or <0.1%) or their functional consequences. We assessed the effect of these pooled variants on T2D risk via the KBAC method 14 embedded in a logistic regression model adjusted for age, gender and BMI. The KBAC method was developed to overcome the problems of detecting rare variant associations in the presence of misclassification. This method was extensively compared to three widely accepted methods (the weighted-sum statistic (WSS), the combined multivariate and collapsing method (CMC) and the comparison of rare variants found exclusively in cases to those found only in controls (RVE)) and was determined to be the most powerful under the assumption of phenotypic effects inversely correlated with MAF 14 . It is noteworthy that the age adjustment used in the assessment of the effect of total loss-of-function MTNR1B variants on T2D risk showed a positive impact on OR estimates. To further examine this phenomenon, we performed a Mantel-Haenszel stratified analysis using three or four strata based on the quantiles of the age distribution without any adjustments for other confounders. Both the ORs and the corresponding P values for T2D risk measured for the three-and four-strata analyses had the same magnitude as those reported by the logistic regression model adjusted for age, gender and BMI, which shows the robustness of our analysis. To address a possible effect of population stratification on our results, we used SNP array data (Illumina Metabochip or Illumina CNV370-Duo DNA arrays), which were available for carriers of partial or total loss-of-function MTNR1B variants. By using the population-specific genotype database released by the HapMap project, we found that 39,000 SNPs present on both chips were identified as good markers of ancestry, as a primary principal-component analysis (PCA) of those variants allowed us to clearly distinguish individuals of European descent (HapMap Utah residents of Northern and Western European ancestry (CEU)), Africans (HapMap Yoruba from Ibadan (YRI)) and Asians (HapMap Japanese from Tokyo (JPT) and Han Chinese from Beijing (CHB)) on the first factorial plan. We then achieved a secondary PCA, including the mutation carriers so as to detect potential admixture. This analysis revealed that it was highly unlikely that the mutation carriers did not have European ancestry ( Supplementary  Fig. 4 ). All statistical analyses were performed with R (version 2.12) and SPSS software (version 14.0 for Windows).
Functional characterization of the MT 2 mutants. Human MTNR1B cDNA was fused at its 5′ end with a sequence encoding a mouse Myc epitope and subcloned into the Flp-In pcDNA5/FRT plasmid (Invitrogen). Each of the 40 nonsynonymous mutations was generated in this plasmid using the QuikChange site-directed mutagenesis kit (Stratagene) and was confirmed by Sanger sequencing of the full-length clone. We established 41 stable FlpIn HEK293 cell lines stably expressing the wild-type receptor or one of the 40 mutant MT 2 receptors according to the manufacturer's recommendations (Invitrogen). Briefly, Flp-In HEK293 cells were co-transfected with each MT 2 -encoding Flp-In pcDNA5/FRT plasmid and the pOG44 vector encoding
